IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
Rhea-AI Summary
IN8bio (NASDAQ: INAB) reported updated Phase 1/2 data for repeat-dose DeltEx™ Drug-Resistant Immunotherapy γδ T cells (DeltEx DRI) in newly diagnosed glioblastoma presented Jan 12, 2026. Across multiple centers (DeltEx DRI N=14; contemporaneous SOC N=10) median progression-free survival mPFS was 13.0 months vs 6.6 months for SOC (+97%). Median overall survival mOS is currently 17.2+ months for DeltEx DRI versus 13.2 months for SOC (+30.3%), with several patients progression-free 1.4–4.6 years. Treatment was well tolerated: no DLTs, no treatment-related SAEs, no CRS, and no ICANS. Company will use late‑2025 financing to support FDA discussions on potential clinical pathways.
Positive
- mPFS 13.0 months vs 6.6 months (+97%)
- mOS 17.2+ months vs 13.2 months (+30.3%)
- No DLTs, no treatment-related SAEs reported
- 57% remained progression-free longer than expected
Negative
- Small treated cohort (DeltEx DRI N=14) limits statistical certainty
- mOS for DeltEx DRI is immature (not yet reached, currently 17.2+ months)
News Market Reaction
On the day this news was published, INAB declined 7.23%, reflecting a notable negative market reaction. Argus tracked a trough of -15.0% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves, with names like RNAZ up 2.96% while others such as APRE, CYCCP, PCSA, and MBIO are down between 3.17% and 5.61%, suggesting INAB’s setup is more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Financing / placement | Neutral | -12.3% | At-the-market private placement to raise up to $40.2M in two tranches. |
| Nov 06 | Earnings & pipeline | Positive | +1.8% | Q3 2025 results plus strengthened γδ T cell and INB-619 preclinical data. |
| Oct 29 | Trial expansion | Positive | -4.8% | Added Ohio State as a new INB-100 Phase 1 site to accelerate enrollment. |
| Oct 27 | Preclinical data | Positive | -1.9% | INB-619 preclinical data showing deep B cell depletion with lower cytokines. |
| Aug 07 | Earnings & GBM data | Positive | +7.4% | Q2 2025 results plus INB-200 GBM data with prolonged progression-free survival. |
Recent news reactions have been mixed: positive clinical and platform updates sometimes aligned with gains but also saw several negative or muted moves, while financing-related news drew a notably negative reaction.
Over the last six months, IN8bio has alternated between clinical, financing, and corporate updates. A private placement on Dec 19, 2025 to raise up to $40.2M drew a -12.32% move. Prior earnings updates in Q2 and Q3 2025 highlighted progress in GBM and INB-619 with share reactions of +7.44% and +1.84%. Multiple clinical-trial releases for INB-100 and INB-200 showed durable remissions and extended mPFS but often saw negative next-day moves, framing today’s GBM data against a backdrop of cautious trading.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 7, 2025 permits IN8bio to offer up to $200,000,000 of various securities over time, subject to the I.B.6 one‑third public-float limitation while float remains below $75.0M. This provides flexibility to raise capital for working capital and corporate purposes via common stock, preferred stock, debt, warrants, rights, or units as detailed in future supplements.
Market Pulse Summary
The stock moved -7.2% in the session following this news. A negative reaction despite favorable GBM efficacy and safety data would fit prior patterns where strong clinical updates sometimes coincided with selling. The results show mPFS of 13.0 months versus 6.6 months for SOC and durable benefit in 57% of treated patients, yet past clinical releases have not always been rewarded. Investors reviewing downside moves may weigh these advances against capital needs under the existing $200,000,000 shelf.
Key Terms
median progression-free survival medical
median overall survival medical
stupp protocol medical
mgmt status medical
biomarker medical
cytokine release syndrome (crs) medical
immune effector cell-associated neurotoxicity (icans) medical
lymphodepleting chemotherapy medical
AI-generated analysis. Not financial advice.
- Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+
97% ) in a control cohort treated with the standard-of-care (SOC) Stupp protocol - Median overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to only 13.2 months for SOC (+
30.3% ) - Treatment remains well tolerated with no treatment related severe adverse events (SAEs) or dose limiting toxicities (DLTs) observed
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials in newly diagnosed glioblastoma (GBM). The prior results were presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The data continue to demonstrate meaningful and durable improvements in progression-free survival when compared with both historical standard-of-care (SOC) Stupp protocol data and concurrently enrolled SOC treated patients.
Patients in both the Phase 1 and 2 who received repeated doses of the Company’s investigational therapy, DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DeltEx DRI) (N=14), experienced substantial improvements in both median progression-free (mPFS) and median overall survival (mOS) across multiple clinical centers. This data is put into greater context compared to contemporaneously enrolled patients treated only with SOC at the same clinical trial sites (N=10), forming a concurrently treated control cohort:
- Median progression-free survival (mPFS): DeltEx DRI 13.0 months vs. 6.6 months with SOC (a +
97% improvement). - Median overall survival (mOS): DeltEx DRI, not yet reached, currently 17.2+ months and rising, compared with 13.2 months (final mOS) for SOC.
- Durability: DeltEx DRI, eight of fourteen patients (
57% ) remained progression-free longer than their expected overall survival (OS) based on age and MGMT status (a biomarker used to stratify GBM patients and impacting response to chemotherapy), compared with just a single patient (10% ) in the control group. - Long-term benefit: Several DeltEx DRI treated patients remain progression-free beyond two years without experiencing any significant DRI related SAEs or DLTs.
William Ho, CEO and Co-founder of IN8bio, commented, “GBM is an extremely aggressive and devastating brain cancer, with a short median survival of only ~12 months and no meaningful innovation in over twenty years. The contrast between our repeat-dose DeltEx DRI patients and the SOC controls treated at the same centers demonstrates a profound improvement. The increase in mPFS, particularly in the newly diagnosed GBM setting, is meaningful time for these patients. The durability of these mPFS results, combined with a well-tolerated safety profile, underscore the potential of our γδ T cell therapy to meaningfully improve newly diagnosed GBM treatment and patient outcomes.”
For the first time, IN8bio presented data from a control group of patients that were contemporaneously enrolled and treated only with the SOC protocols at the same clinical centers with the same treating physicians as the DeltEx DRI cohorts. The SOC control patients performed in-line with expectations based on historical GBM mPFS of 6.9 months, despite a greater number of patients receiving gross total resections. This demonstrates both the aggressive nature of GBM, even with SOC treatment, and the significant need for new treatment options. The funds received from IN8bio’s recent financing announced late in 2025 will support further discussions with the FDA on potential clinical pathways, including any potential for accelerated approval.
Across both Phase 1, INB-200, and Phase 2, INB-400, trials at multiple centers, DeltEx DRI γδ T cells continued to demonstrate a well-tolerated safety profile, with:
- No DLTs
- No cytokine release syndrome (CRS)
- No immune effector cell-associated neurotoxicity (ICANS)
- No unexpected infections or SAEs
Kate Rochlin, PhD, Chief Operating Officer, IN8bio, added, “These results show a consistent biological and clinical story. In the DeltEx DRI treated patients, we observed persistent and elevated levels of γδ T cells in circulation, immune cell infiltration within the tumors, and broader systemic immune activation. This is significant in understanding the immune impact in patients treated with this therapy, particularly in a setting traditionally considered a “cold” tumor combined with long-term lymphodepleting chemotherapy. Furthermore, these findings indicate that localized intracranial delivery of DeltEx DRI can drive systemic immune responses, an aspect that could be important in fighting GBM. This is a disease marked by profound treatment-induced lymphodepletion, rapid progression, and poor outcomes.
The data presented at SNO was the first time IN8bio had presented multi-center DeltEx treated and control SOC patient data from the both 1 and Phase 2 trials. Across all sites, early trends in mPFS and mOS were consistent with the original INB-200 trial, reinforcing:
- Reproducibility across clinical centers
- Scalability of the repeated-dose approach
- A strong foundation for further development
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell product candidates for unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-100, is focused on acute myeloid leukemia, evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The Company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and INB-600, advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
What mPFS did IN8bio (INAB) report for DeltEx DRI in January 2026?
How does IN8bio's reported mOS for DeltEx DRI compare to SOC in the Phase 1/2 data?
Were there serious safety issues reported for IN8bio's DeltEx DRI (INAB)?
How many patients received repeat-dose DeltEx DRI in the updated IN8bio data?
Did IN8bio include a control group in the January 2026 disclosure and what was it?
What next steps did IN8bio indicate after the updated DeltEx DRI results?
